California Pharmacist vol. 72, no. 3 FALL 2025 - Flipbook - Page 22
¢
©
¨
¡
¢
Current Evidence: Cardiovascular Outcomes Trials
Semaglutide
ª
¢ ª«
©¦«
¦P¬ ª
«
¥¦« ¦
«ª ª
¦« ¦¦ £
¢
®ª
«
¨ª
« ª¦« ª
ª« ª©¦«
©ª
ª
¢¦
£
ª
¦
©
P¬ ª ªP
¬
ª
ª
©¦« ¦«
© «
©¦¦« ¦
¡
©« ª¦« ¦ª
ª«
©¥¦« ª ¦ 11
Table 1. Pharmacologic Characteristics of GLP-1 RAs and and Tirzepatide
Agents
Dulaglutide
Exenatide
Liraglutide
Lixisenatide
Semaglutide
Tirzepatide
(Dual GIP and
GLP-1 RA)
Dosage Forms
Half-Lives
Trulicity
SC
5 days
Dosing Ranges5
0.75–4.5 mg weekly
Byetta
SC
2.4 h
5 –10 mcg twice daily
Bydureon BCise
SC
2 weeks
2 mg weekly
Victoza
SC
Saxenda
SC
Adlyxin
SC
Ozempic
SC
Wegovy
SC
Rybelsus
PO
Mounjaro, Zepbound
SC
Brand Names
13 h
0.6–1.8 mg daily
0.6–3 mg daily
3h
10–20 mcg daily
0.25–2.0 mg weekly
1 week
0.25–2.4 mg weekly
7–14 mg daily
5 days
5–15 mg weekly
Abbreviations: GIP, gastric inhibitory polypeptide; GLP-1 RA, glucagon-like peptide-1 receptor agonists: SC, subcutaneous.
20
vol. 72, no.3 | California Pharmacist
